Biopoin market set for rapid growth on CKD and anemia demand
The Business Research Company says the global Biopoin market is expanding as chronic kidney disease, chemotherapy-related anemia and broader use of biosimilar epoetins push demand higher. North America led in 2025, while Asia-Pacific is projected to grow the fastest through the forecast period.
Why it matters: - The Biopoin market is tied to two growing care needs: anemia linked to chronic kidney disease and anemia connected to cancer treatment. - Rising demand for advanced anemia management could support broader use of epoetin-based therapies across hospitals and oncology support care. - The market outlook points to more use of biosimilar epoetins and long-acting anemia treatments as health systems try to improve patient quality of life.
What happened: - The Business Research Company published its Biopoin Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Nov. 2, 2026. - The report says the Biopoin market has expanded on the back of clinical success in epoetin therapies, a larger dialysis patient population, chemotherapy-induced anemia, hospital anemia management protocols and better hemoglobin monitoring. - The report forecasts further growth from 2026 to 2030. - A free sample of the report is available. - A full market report is also available.
The details: - Biopoin is a biopharmaceutical product used to treat anemia in adults with chronic kidney failure and in patients receiving chemotherapy for non-myeloid cancers. - The product contains epoetin theta, a recombinant form of erythropoietin that stimulates red blood cell production. - Higher hemoglobin levels help reduce anemia-related fatigue and weakness. - Chronic kidney disease is a key growth driver because reduced kidney function lowers erythropoietin production and can trigger anemia. - The report links CKD growth to rising diabetes, hypertension and poor dietary habits. - The report cites an October 2024 UK National Health Service update saying nearly half of adults aged 75 and older have some stage of CKD, with more than a third in severe stages. - The report also cites a June 2023 Oxford Academic study projecting UK CKD cases will rise 4% between 2022 and 2032, from 8.27 million to 8.61 million. - Anemia prevalence is another demand driver because the condition limits the blood’s ability to carry oxygen. - The report points to nutrient deficiencies, including iron, vitamin B12 and folate, as major causes of anemia. - World Health Organization data from April 2024 showed about 30.7% of women ages 15 to 49 had anemia in 2023. - The report says personalized medicine trends are also supporting Biopoin development as therapies become more targeted. - The Personalized Medicine Coalition said in February 2024 that the FDA approved 16 new personalized treatments for rare diseases in 2023, up from 6 in 2022. - The report says new 2026 editions include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables.
Between the lines: - The report frames Biopoin as part of a wider shift toward anemia therapies that are more precise, longer-acting and tied to supportive care rather than one-off treatment. - The combination of CKD growth, aging populations and oncology demand suggests the market’s upside depends as much on chronic disease prevalence as on product innovation. - North America’s lead in 2025 signals an established reimbursement and treatment base, while faster Asia-Pacific growth points to expanding access and patient volume.
What's next: - The report expects growth to continue as chronic renal failure cases rise and biosimilar epoetin access expands. - Oncology supportive care use is expected to broaden, adding another demand stream for anemia management products. - The forecast period also points to more emphasis on managing anemia-related fatigue and improving quality of life for chronic anemia patients. - The report says Asia-Pacific will be the fastest-growing region over the forecast period, while North America remains the largest market in 2025.
The bottom line: - Biopoin’s market case rests on a simple trend: more patients need anemia treatment, and health systems want therapies that are more targeted, more durable and easier to integrate into long-term care.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
One World Daily Brief
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.